Abstract
Small-cell lung cancer (SCLC) is a particularly aggressive form of lung cancer and is associated with a poor prognosis, rapid tumor growth, and early metastasis. Currently, the cornerstone of treatment in SCLC consists of combination therapy, with platinum/etoposide being the regimen of choice. Unfortunately, even with these advances in treatment, the median survival for patients with limited-stage disease is 10-15 months and 7-11 months for patients with extensive-stage disease. New treatment mechanisms need to be explored in order to extend the survival of SCLC patients. One such new treatment is the topoisomerase I inhibitor, irinotecan. This drug represents a promising advancement in the treatment of SCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
